Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy

Blood

Volumn 92, Issue 3, 1998, Pages 802-809

  Drach, Johannes ^a   Ackermann, Jutta ^b   Fritz, Elke ^b   Krömer, Elisabeth ^b   Schuster, Rudolf ^b   Gisslinger, Heinz ^b   DeSantis, Maria ^b   Zojer, Niklas ^b   Fiegl, Michael ^b   Roka, Sebastian ^b   Schuster, Judith ^b   Heinz, Renate ^b   Ludwig, Heinz ^b   Huber, Heinz ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DIAGNOSTIC VALUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0032147210     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.3.802     Document Type: Article

References (48)

1. Isobe M, Emmanuel B, Givol D, Oren M, Croce C: Localization of gene for human p53 tumour antigen to band 17p13. Nature 320:84, 1986
2. Vogelstein B, Kanzler KW: p53 function and dysfunction. Cell 70:523, 1992
3. Hollstein M, Sidransky D, Vogelstein B, Harris CC: P53 mutations in human cancers. Science 253:49, 1991
4. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B: Multifactorial analysis of p53 alteration in human cancer: A review. Int J Cancer 57:1, 1994
5. Horio Y. Takahashi T, Kuroishi T, Hibi K. Suyama M, Nimi T, Shimokata K. Yamakawa K, Nakamura Y, Ueda R. et al: Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 53:1, 1993
6. Thorlacius S, Borresen AL, Eyfjord JE: Somatic p53 mutations in human breast carcinomas in an Icelandic population: A prognostic factor. Cancer Res 53:1637, 1993
7. Preudhomme C, Fenaux P: The clinical significance of mutations of the p53 tumour suppressor gene in haematological malignancies. Br J Haematol 98:502, 1997
8. Lai JL, Preudhomme C. Zandecki M, Flactif M, Vanrumbeke M, Wattel E, Fenaux P: Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations. Leukemia 9:370, 1995
9. Ichikawa A. Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K, Saito H, Hotta T: Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 337:529, 1997
10. Portier M, Moles J-P. Mazars G-R, Jeanteur P, Bataille R, Klein B, Theillet C: p53 and RAS gene mutations in multiple myeloma. Oncogene 7:2539, 1992
11. Preudhomme C. Facon T. Zandecki M, Vanrumbeke M, Lai JL, Nataf E, Loucheux-Lefebvre MH, Kerckaert JP, Fenaux P: Rare occurrence of P53 gene mutations in multiple myeloma. Br J Haematol 81:440, 1992
12. Willems PMW, Kuypers A, Meijerink J, Holdrinet R. Mensink E: Sporadic mutations of the p53 gene in multiple myeloma and no evidence for germline mutations in three familial myeloma pedigrees. Leukemia 7:986. 1993
13. Neri A, Baldini L, Trecca D, Cro L, Polli E, Maiolo AT: p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 81:128, 1993
14. Corradini P, Inghirami G. Astolfi M, Ladetto M, Voena C, Ballerini P, Gu W, Nilsson K, Knowles DM, Boccadoro M, Pileri A, Dalla-Favera R: Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. Leukemia 8:758, 1994
15. Owen RG, Davis SAA. Randerson J, Rawstron AC, Davies F, Child JA, Jack AS, Morgan GJ: p53 gene mutations in multiple myeloma. J Clin Pathol: Mol Pathol 50:18, 1997
16. Döhner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, Diehl D, Schlenk R, Coy J, Stilgenbauer S, Volkmann M, Galle PR, Poustka A, Hunstein W, Lichter P: p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85:1580, 1995
17. Dewald GW, Kyle RA, Hicks GA, Greipp PR: The clinical Significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 66:380, 1985
18. Gould J. Alexanian R. Goodacre A, Pathak S, Hecht B, Barlogie B: Plasma cell karyotype in multiple myeloma. Blood 71:453. 1988
19. Weh HJ, Gutensohn K, Selbach J, Kruse R, Wacker-Backhaus G, Seeger D, Fiedler W, Fett W, Hossfeld DK: Karyotype in multiple myeloma and plasma cell leukaemia. Eur J Cancer 29A: 1269, 1993
20. Lai JL, Zandecki M, Mary JY, Bernardi F, Izydorczyk V, Flactif M, Morel P, Jouet JP, Bauters F, Facon T: Improved cytogenetics in multiple myeloma: A study of 151 patients including 117 patients at diagnosis. Blood 85:2490, 1995
21. Sawyer JR, Waldron JA, Jagannath S, Barlogie B: Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 82:41, 1995
22. Calasanz MJ, Cigudosa JC, Odero MD, Ferreira C, Ardanaz MT, Fraile A, Carrasco JL, Sole F, Cuesta B, Gullon A: Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: Primary breakpoints and clinical correlations. Genes Chromosomes Cancer 18:84, 1997
23. Drach J, Schuster J, Nowotny H, Angerler J, Rosenthal F, Fiegl M, Rothermundt C, Gsur A, Jäger U, Heinz R, Lechner K, Ludwig H, Huber H: Multiple myeloma: High incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Res 55:3854, 1995
24. Flactif M, Zandecki M, Lai JL, Bernardi F, Obein V, Bauters F, Facon T: Interphase fluorescence in situ hybridization (FISH) as a powerful tool for the detection of aneuploidy in multiple myeloma. Leukemia 9:2109, 1995
25. Tabernero D, San Miguel JF, Garcia-Sanz R, Najera L, Garcia-Isidoro M, Perez-Simon JA, Gonzalez M, Wiegant J, Raap AK, Orfao A: Incidence of numerical chromosome changes in multiple myeloma. Fluorescence in situ hybridization analysis using 15 chromosomespecific probes. Am J Pathol 149:153, 1996
26. Zandecki M, Lai JL, Facon T: Multiple myeloma: Almost all patients are cytogenetically abnormal. Br J Haematol 94:217, 1996
27. Chronic Leukemia-Myeloma Task Force: Proposed guidelines for protocol studies: II. Plasma cell myeloma. Cancer Chemother Rep 4:145, 1973
28. Fain PR, Solomon E, Ledbetter: Second International Workshop on human chromosome 17. Cytogenet Cell Genet 57:66, 1991
29. Drach J, Angerler J, Schuster J, Rothermundt C, Thalhammer R, Haas OA, Jäger U, Fiegl M, Geissler K, Ludwig H, Huber H: Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood 86:3915. 1995
30. Schweizer D: Simultaneous fluorescent staining of R bands and specific heterochromatic regions (DA-DAPI bands) in human chromosomes. Cytogenet Cell Genet 27:190, 1980
31. Schweizer D: Counterstain-enhanced chromosome banding. Hum Genet 57:1, 1981
32. Mitelman F: ISCN Guidelines for Cancer Cytogenetics. Supplement to an International System for Human Cytogenetic Nomenclature. Basel, Switzerland, Karger, 1991
33. Avet-Loiseau H, Andree-Ashley LE, Moore D, Melloin MP, Feusner J, Bataille R, Pallavicini MG: Molecular cytogenetic abnormalities in multiple myeloma and plasma cell leukemia measured using comparative genomic hybridization. Genes Chromosomes Cancer 19: 124, 1997
34. van den Berghe H: Chromosomes in plasma-cell malignancies. Eur J Haematol 45:47, 1990
35. INK4b/MTS2 in pediatrie acute lymphoblastic leukemia. Blood 85:2331, 1995
36. Leblanc T. Derre J. Flexor M, Le Coniat M, Leroux D, Rimokh R, Larsen C-J, Berger R: FISH analysis of translocation s involving the short arm of chromosome 9 in lymphoid malignancies. Genes Chromosomes Cancer 19:273, 1997
37. Kobayashi H, Montgomery KT. Bohlander SK, Adra CN, Lim BL, Kucherlapati RS, Donis-Keller H, Holt MS, Le Beau MM, Rowley JD: Fluorescence in situ hybridization mapping of translocations and deletions involving the short arm of human chromosome 12 in malignant hematologie diseases. Blood 84:3473, 1994
38. Kobayashi H. Rowley JD: Identification of cytogenetically undetected 12pl3 translocations and associated deletions with fluorescence in situ hybridization. Genes Chromosomes Cancer 12:66, 1995
39. Höglund M, Johansson B, Pedersen-Bjergaard J, Marynen P, Mitelman F: Molecular characterization of 12p abnormalities in hematologie malignancies: Deletion of KIP 1, rearrangement of TEL, and amplification of CCND2. Blood 87:324, 1996
40. Wlodarska I. Marynen P, La Starza R, Mecucci C, van den Berghe H: The ETV6, CDKN1B and D12S178 loci are involved in a segment commonly deleted in various 12p aberrations in different hematological malignancies. Cytogenet Cell Genet 72:229, 1996
41. Andreasson P, Johansson B, Arheden K, Billström R, Mitelman F, Höglund M: Deletions of CDKN1B and ETV6 in acute myeloid leukemia and myelodysplastic syndromes without cytogenetic evidence of 12p abnormalities. Genes Chromosomes Cancer 19:77, 1997
42. Momand J, Zambetti GP, Olson DC, George D, Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237, 1992
43. Teoh G.,Urashima M, Ogata A, Chauhan D, DeCaprio JA, Treon SP, Schlossman RL, Anderson KC: MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells. Blood 90:1982, 1997
44. Lotem J, Sachs L: Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood 82:1092, 1993
45. Lane D: p53, guardian of the genome. Nature 358:15, 1993
46. Carson DA, Lois A: Cancer progression and p53. Lancet 346:1009, 1995
47. Tricot G, Sawyer J, Jagannath S, Bracy D, Mattox S, Vesole D, Naucke S, Barlogie B: Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 86:4250, 1995
48. Tricot G, Sawyer JR, Jagannath S, Desikan KR, Siegel R, Naucke S, Mattox S, Bracy D, Munshi N, Barlogie B: Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol 15:2659, 1997